Shandong Boan files Brazil marketing application for BA9101 aflibercept biosimilar with ANVISA

• Shandong Boan Biotechnology filed a marketing authorization application in Brazil with ANVISA for BA9101, an Eylea biosimilar eye injection.
• The filing targets adult wet age-related macular degeneration, diabetic macular edema.
• BA9101 won China approval in November 2025 under the brand name Boyoujing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260805-12273989), on August 05, 2026, and is solely responsible for the information contained therein.